Major adverse cardiovascular events (MACE) in patients with severe COVID-19 registered in the ISARIC WHO clinical characterization protocol: A prospective, multinational, observational study
Authors' conclusion
Patients with severe COVID-19 frequently develop MACE, which is independently associated with worse clinical outcomes.
Study context
- Population
- Patients with severe COVID-19 registered in the ISARIC WHO clinical characterization protocolISARIC database
- Participants
- 49,479 patients
- Exposure
- MACE vs no MACE
- MACEn = 8,829
- No MACEn = 40,650reference
- Outcome
- MACE cumulative incidence during hospital stay
Methodological detailsmultinational, multicentre
- Multinational
- Multicentre
Main finding
As reported in the abstract
MACE cumulative incidence during hospital stay
17.8%
8829/49,479
Observational data: associations, not effects.
Further findings
| Outcome | MACE | No MACE | OR (95% CI) | |
|---|---|---|---|---|
| 28-day mortality · adjusted for confounders | 63.1% | 35.6% | 1.36 (1.33–1.39) | |
| 90-day mortality · adjusted for confounders | 69.9% | 37.8% | 1.47 (1.43–1.50) | |
| 0.512Odds ratio (log scale) |
- 28-day mortality: unadjusted p < 0.001
- 90-day mortality: unadjusted p < 0.001
Risk factors for MACE
- Older age, CKD or CVD, smoking history, and vasopressors or invasive mechanical ventilation at admission independently associated with MACE
Original publication
Major adverse cardiovascular events (MACE) in patients with severe COVID-19 registered in the ISARIC WHO clinical characterization protocol: A prospective, multinational, observational study. J Crit Care. Published 9 May 2023. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →